Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaldehyde | 2 | 2026 | 5 | 1.250 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2026 | 178 | 0.850 |
Why?
|
| Prostatic Neoplasms | 4 | 2026 | 302 | 0.690 |
Why?
|
| Electrocardiography | 2 | 2025 | 398 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 165 | 0.650 |
Why?
|
| Breath Tests | 3 | 2009 | 14 | 0.630 |
Why?
|
| Heart Failure | 4 | 2025 | 253 | 0.630 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 168 | 0.630 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 220 | 0.570 |
Why?
|
| Mouth Neoplasms | 2 | 2017 | 64 | 0.560 |
Why?
|
| Fanconi Anemia | 1 | 2017 | 3 | 0.530 |
Why?
|
| Androgen Antagonists | 3 | 2026 | 20 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 347 | 0.470 |
Why?
|
| Facial Injuries | 2 | 2012 | 3 | 0.460 |
Why?
|
| Lasers | 4 | 2026 | 68 | 0.410 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2025 | 9 | 0.390 |
Why?
|
| Heart-Assist Devices | 2 | 2025 | 33 | 0.380 |
Why?
|
| Protective Devices | 1 | 2012 | 5 | 0.370 |
Why?
|
| Spectrophotometry, Infrared | 3 | 2026 | 26 | 0.370 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 122 | 0.360 |
Why?
|
| Athletic Injuries | 1 | 2012 | 122 | 0.330 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 176 | 0.320 |
Why?
|
| Diagnosis, Oral | 2 | 2011 | 2 | 0.320 |
Why?
|
| Haptoglobins | 1 | 2009 | 22 | 0.310 |
Why?
|
| Cattle Diseases | 1 | 2009 | 18 | 0.310 |
Why?
|
| Humans | 24 | 2026 | 28851 | 0.310 |
Why?
|
| Respiratory Tract Infections | 1 | 2009 | 37 | 0.310 |
Why?
|
| Mandibular Fractures | 1 | 2008 | 3 | 0.300 |
Why?
|
| Emergency Treatment | 1 | 2008 | 26 | 0.290 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2026 | 47 | 0.290 |
Why?
|
| Aged | 9 | 2026 | 5598 | 0.280 |
Why?
|
| Male | 15 | 2026 | 13921 | 0.270 |
Why?
|
| Spectrophotometry | 1 | 2007 | 34 | 0.270 |
Why?
|
| Optics and Photonics | 1 | 2007 | 23 | 0.270 |
Why?
|
| Chemoradiotherapy | 2 | 2024 | 50 | 0.260 |
Why?
|
| CTLA-4 Antigen | 1 | 2026 | 11 | 0.240 |
Why?
|
| Fermentation | 1 | 2026 | 52 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 1 | 2026 | 80 | 0.230 |
Why?
|
| Wearable Electronic Devices | 1 | 2025 | 13 | 0.230 |
Why?
|
| Pathology, Oral | 1 | 2005 | 1 | 0.230 |
Why?
|
| Oral Medicine | 1 | 2005 | 1 | 0.230 |
Why?
|
| Heart Transplantation | 1 | 2025 | 43 | 0.230 |
Why?
|
| Ethanol | 1 | 2026 | 125 | 0.220 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 6 | 0.220 |
Why?
|
| Baroreflex | 1 | 2024 | 6 | 0.220 |
Why?
|
| Salvage Therapy | 1 | 2024 | 37 | 0.220 |
Why?
|
| Capecitabine | 1 | 2024 | 4 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2024 | 39 | 0.220 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 10 | 0.220 |
Why?
|
| Scrotum | 1 | 2024 | 9 | 0.220 |
Why?
|
| Machine Learning | 1 | 2025 | 96 | 0.210 |
Why?
|
| Female | 11 | 2025 | 15624 | 0.200 |
Why?
|
| Middle Aged | 9 | 2026 | 7414 | 0.200 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 194 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 79 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 218 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 103 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 433 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2021 | 54 | 0.170 |
Why?
|
| Zygomatic Fractures | 1 | 2000 | 2 | 0.170 |
Why?
|
| Orbital Fractures | 1 | 2000 | 6 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2020 | 11 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 377 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 58 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 38 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 40 | 0.150 |
Why?
|
| Pulmonary Artery | 1 | 2019 | 69 | 0.150 |
Why?
|
| African Americans | 1 | 2021 | 352 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2020 | 266 | 0.140 |
Why?
|
| Gases | 2 | 2007 | 23 | 0.130 |
Why?
|
| Prostatectomy | 2 | 2026 | 90 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2025 | 1280 | 0.120 |
Why?
|
| Adult | 5 | 2024 | 8024 | 0.110 |
Why?
|
| Nitric Oxide | 2 | 2006 | 153 | 0.100 |
Why?
|
| Biomarkers | 2 | 2023 | 776 | 0.100 |
Why?
|
| Ireland | 1 | 2012 | 16 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 73 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 78 | 0.090 |
Why?
|
| Violence | 1 | 2012 | 31 | 0.090 |
Why?
|
| Remote Consultation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Lacerations | 1 | 2011 | 8 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2011 | 76 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2011 | 64 | 0.080 |
Why?
|
| Wound Healing | 1 | 2011 | 126 | 0.080 |
Why?
|
| Absorption | 2 | 2007 | 14 | 0.080 |
Why?
|
| United Kingdom | 2 | 2011 | 78 | 0.080 |
Why?
|
| Beverages | 1 | 2009 | 24 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2009 | 23 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 33 | 0.080 |
Why?
|
| Oral Hemorrhage | 1 | 2008 | 1 | 0.070 |
Why?
|
| Water | 2 | 2007 | 135 | 0.070 |
Why?
|
| Airway Obstruction | 1 | 2008 | 20 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2026 | 2426 | 0.070 |
Why?
|
| Cattle | 1 | 2009 | 389 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2024 | 357 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 289 | 0.070 |
Why?
|
| Young Adult | 3 | 2011 | 2833 | 0.070 |
Why?
|
| Calibration | 1 | 2007 | 29 | 0.070 |
Why?
|
| United States | 2 | 2025 | 2222 | 0.060 |
Why?
|
| Time Factors | 2 | 2009 | 1613 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2009 | 272 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2007 | 134 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2026 | 1 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2026 | 2 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2026 | 32 | 0.060 |
Why?
|
| Prednisone | 1 | 2026 | 54 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2026 | 53 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 997 | 0.060 |
Why?
|
| Photoplethysmography | 1 | 2025 | 2 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2024 | 2635 | 0.060 |
Why?
|
| Mouth Diseases | 1 | 2005 | 6 | 0.060 |
Why?
|
| Education, Dental | 1 | 2005 | 10 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2026 | 303 | 0.060 |
Why?
|
| Emergency Medicine | 1 | 2005 | 15 | 0.060 |
Why?
|
| Cardiac Catheterization | 1 | 2025 | 114 | 0.060 |
Why?
|
| Colostomy | 1 | 2024 | 9 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 15 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 18 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2024 | 73 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2025 | 124 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2026 | 143 | 0.050 |
Why?
|
| Penis | 1 | 2024 | 17 | 0.050 |
Why?
|
| Education, Medical | 1 | 2005 | 68 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 98 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 245 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2023 | 44 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2023 | 60 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2005 | 235 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2023 | 73 | 0.050 |
Why?
|
| Adolescent | 3 | 2011 | 3193 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2023 | 112 | 0.050 |
Why?
|
| Phenotype | 1 | 2024 | 685 | 0.050 |
Why?
|
| Asthma | 1 | 2002 | 60 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 163 | 0.040 |
Why?
|
| Physics | 1 | 2021 | 2 | 0.040 |
Why?
|
| Hawaii | 1 | 2021 | 12 | 0.040 |
Why?
|
| Drug Industry | 1 | 2021 | 15 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 107 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 521 | 0.040 |
Why?
|
| Zygoma | 1 | 2000 | 3 | 0.040 |
Why?
|
| Orbit | 1 | 2000 | 12 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 68 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 155 | 0.040 |
Why?
|
| Radiography | 1 | 2000 | 203 | 0.040 |
Why?
|
| Child | 2 | 2011 | 2287 | 0.040 |
Why?
|
| Jugular Veins | 1 | 2019 | 13 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 2065 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 243 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 524 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 218 | 0.040 |
Why?
|
| Animals | 1 | 2009 | 10684 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2011 | 10 | 0.020 |
Why?
|
| Sutures | 1 | 2011 | 15 | 0.020 |
Why?
|
| Photography | 1 | 2011 | 19 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Phone | 1 | 2011 | 20 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2011 | 46 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 96 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 222 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 126 | 0.020 |
Why?
|
| Students, Medical | 1 | 2011 | 102 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2009 | 26 | 0.020 |
Why?
|
| Caffeine | 1 | 2009 | 39 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2009 | 35 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 96 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 303 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 96 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 172 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2009 | 89 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 173 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 173 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 422 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 310 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 382 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1173 | 0.020 |
Why?
|
| Solutions | 1 | 2006 | 31 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 19 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 73 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 94 | 0.010 |
Why?
|